# The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

> **NCT00301366** · PHASE3 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 38 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **DRUG:** alpha-1 proteinase inhibitor (human)

## Key facts

- **NCT ID:** NCT00301366
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301366, "The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00301366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*